When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ESALF - Eisai and Biogen launch Phase 3 BAN2401 program in asymptomatic alzheimer's disease
Eisai Co Ltd
Eisai (OTCPK:ESALF) in collaboration with Alzheimer's Clinical Trials Consortium and Biogen (NASDAQ:BIIB) has initiated a new global Phase 3 clinical study (AHEAD 3-45) with BAN2401, an anti-amyloid beta (A?) protofibril antibody.
More news on: Eisai Co., Ltd., Biogen Inc., Eisai Co., Ltd., Healthcare stocks news,